MiNK Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 5.46 million compared to USD 7.77 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.23 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9275 USD | +6.46% | +5.84% | -13.32% |
Mar. 21 | Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024 | |
Mar. 21 | MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.32% | 32.18M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- INKT Stock
- News MiNK Therapeutics, Inc.
- MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023